表紙
市場調查報告書

白喉:開發中產品分析

Diphtheria - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 213116
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
白喉:開發中產品分析 Diphtheria - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 85 Pages
簡介

白喉是細菌性的感染疾病,從喉嚨、鼻粘膜發病。如果不治療,腎臟和神經系統,心臟會受到嚴重的損傷。主要的症狀,有喉嚨的疼痛和聲音嘶啞、頸部的淋巴節腫脹、鼻涕、發熱發冷、倦怠感等。治療方法有抗毒素和抗生素等。

本報告提供全球各國的白喉治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

白喉概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • Boryung Pharmaceutical Co Ltd
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Indian Immunologicals Ltd
  • 化血研
  • LG Chem, Ltd.
  • Prometheon Pharma LLC
  • Sanofi
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Shantha Biotechnics Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

白喉:暫停中的計劃

白喉:開發中止的產品

白喉:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12215IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2020, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 10, 3, 8, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diphtheria - Overview
    • Diphtheria - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Diphtheria - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Diphtheria - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Beijing Tiantan Biological Products Co Ltd
    • Biken Co Ltd
    • Biological E Ltd
    • BioNet- Asia Co Ltd
    • Boryung Pharmaceutical Co Ltd
    • Cadila Healthcare Ltd
    • CanSino Biologics Inc
    • Changchun Bcht Biotechnology Co Ltd
    • Chongqing Zhifei Biological Products Co Ltd
    • Emergent BioSolutions Inc
    • GC Pharma
    • GlaxoSmithKline Plc
    • KM Biologics Co Ltd
    • LG Chem Ltd
    • Novo Medi Sciences Pvt Ltd
    • Olymvax Biopharmaceuticals Inc
    • Panacea Biotec Ltd
    • Sanofi
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Shantha Biotechnics Pvt Ltd
    • Yisheng Biopharma Co Ltd
  • Diphtheria - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Adacel plus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-1004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diphtheria antitoxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTcP vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3104A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-315 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diphtheria - Dormant Projects
  • Diphtheria - Discontinued Products
  • Diphtheria - Product Development Milestones
    • Featured News & Press Releases
      • Jan 14, 2019: FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination
      • Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
      • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
      • Nov 10, 2014: Shantha's Pentavalent Pediatric Vaccine launched in India
      • May 05, 2014: Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
      • Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
      • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
      • Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
      • Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
      • Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
      • Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Diphtheria, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Diphtheria - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2020
  • Diphtheria - Pipeline by Biken Co Ltd, H1 2020
  • Diphtheria - Pipeline by Biological E Ltd, H1 2020
  • Diphtheria - Pipeline by BioNet- Asia Co Ltd, H1 2020
  • Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
  • Diphtheria - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Diphtheria - Pipeline by CanSino Biologics Inc, H1 2020
  • Diphtheria - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
  • Diphtheria - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Diphtheria - Pipeline by Emergent BioSolutions Inc, H1 2020
  • Diphtheria - Pipeline by GC Pharma, H1 2020
  • Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Diphtheria - Pipeline by KM Biologics Co Ltd, H1 2020
  • Diphtheria - Pipeline by LG Chem Ltd, H1 2020
  • Diphtheria - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Diphtheria - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
  • Diphtheria - Pipeline by Panacea Biotec Ltd, H1 2020
  • Diphtheria - Pipeline by Sanofi, H1 2020
  • Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2020
  • Diphtheria - Pipeline by Serum Institute of India Ltd, H1 2020
  • Diphtheria - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020
  • Diphtheria - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Diphtheria - Dormant Projects, H1 2020
  • Diphtheria - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Diphtheria - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Diphtheria, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020